Peptide PEGylation

By: Matthias Junkers, Aldrich ChemFiles 2007, 7.2, 15.

Circulatory half-life is a key success factor of new drugs. In this respect, modification of potential candidates ranging from non-peptidic molecules to peptides and proteins with polyethyleneglycol chains (PEGs) offers numerous advantages. PEGs are non-toxic, non-immunogenic, non-antigenic, highly soluble in water and FDA approved.1 The PEGylated conjugates show a decreased degradation by metabolic enzymes and a reduction or elimination of protein immunogenicity. Thus Pettit et al. found a 50-fold enhancement of residence in the organism of PEGylated IL-15 (Interleukin).2

Sigma-Aldrich is pleased to provide you with a continuously growing and diverse portfolio of PEGs: 27 new products that will help you improve the success of your drug discovery research.

back to top Back to Top

Materials

     

References

  1. Veronese, F. M.; Pasut, G. Drug Disc. Tod. 2005, 21, 1451.
  2. Pettit, D. K. et al. J. of Biol. Chem. 1997, 272, 2312.

back to top Back to Top

Related Links